Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,396 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
Revenue
1,644
391
434
402
415
382
Revenue Growth (YoY)
1%
2%
-2%
6%
-1%
4%
Cost of Revenue
705
164
183
172
186
167
Gross Profit
938
227
251
229
229
215
Selling, General & Admin
660
166
156
166
170
164
Research & Development
79
19
19
19
21
20
Operating Expenses
754
189
179
189
195
188
Other Non Operating Income (Expenses)
2
4
0
0
-2
0
Pretax Income
-535
-2
4
-6
-530
-30
Income Tax Expense
-40
2
6
-1
-46
-4
Net Income
-495
-4
-1
-5
-484
-25
Net Income Growth
1,668%
-84%
-105%
-50%
3,933%
733%
Shares Outstanding (Diluted)
76.95
76.95
76.77
76.75
76.69
76.46
Shares Change (YoY)
1%
1%
0%
0%
-1%
-2%
EPS (Diluted)
-6.44
-0.06
-0.02
-0.07
-6.31
-0.33
EPS Growth
1,610%
-82%
-109%
-50%
3,840%
684%
Free Cash Flow
-10
-5
-19
25
-11
-40
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
57.05%
58.05%
57.83%
56.96%
55.18%
56.28%
Operating Margin
11.19%
9.46%
16.58%
9.95%
7.95%
6.8%
Profit Margin
-30.1%
-1.02%
-0.23%
-1.24%
-116.62%
-6.54%
Free Cash Flow Margin
-0.6%
-1.27%
-4.37%
6.21%
-2.65%
-10.47%
EBITDA
199
40
75
43
36
29
EBITDA Margin
12.1%
10.23%
17.28%
10.69%
8.67%
7.59%
D&A For EBITDA
15
3
3
3
3
3
EBIT
184
37
72
40
33
26
EBIT Margin
11.19%
9.46%
16.58%
9.95%
7.95%
6.8%
Effective Tax Rate
7.47%
-100%
150%
16.66%
8.67%
13.33%
Follow-Up Questions
What are Integra Lifesciences Holdings Corp's key financial statements?
According to the latest financial statement (Form-10K), Integra Lifesciences Holdings Corp has a total asset of $0, Net loss of $0
What are the key financial ratios for IART?
Integra Lifesciences Holdings Corp's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is Integra Lifesciences Holdings Corp's revenue broken down by segment or geography?
Integra Lifesciences Holdings Corp largest revenue segment is Codman Specialty Surgical, at a revenue of 1,200,511,000 in the most earnings release.For geography, United States is the primary market for Integra Lifesciences Holdings Corp, at a revenue of 1,204,745,000.
Is Integra Lifesciences Holdings Corp profitable?
no, according to the latest financial statements, Integra Lifesciences Holdings Corp has a net loss of $0
Does Integra Lifesciences Holdings Corp have any liabilities?
no, Integra Lifesciences Holdings Corp has liability of 0
How many outstanding shares for Integra Lifesciences Holdings Corp?
Integra Lifesciences Holdings Corp has a total outstanding shares of 0